Literature DB >> 18288956

Lack of interaction of the NMDA receptor antagonists dextromethorphan and dextrorphan with P-glycoprotein.

M Kanaan1, Y Daali, P Dayer, Jules Desmeules.   

Abstract

The anti-N-methyl-D-aspartate (NMDA) effect of dextromethorphan (DEM) seems to be mainly related to the unchanged drug rather than to its more potent metabolite dextrorphan (DOR). The aim of our study was to assess the involvement of P-glycoprotein (P-gp) and pH conditions in the transmembranal transport of these two NMDA antagonists, using a human in vitro Caco-2 cell monolayer model. Transmission electron microscopy, transepithelial electrical resistance, [(3)H]-mannitol permeability, Western blot analysis and the bidirectional transport of the positive controls, rhodamine and digoxine were used to confirm model's integrity and validity. The bidirectional transport of DEM and DOR (1 to 100microM) across the monolayers was investigated in the presence and absence of the P-gp inhibitor cyclosporine A (10microM) at two pH conditions (pH 6.8/7.7-pH 7.4/7.4) and assessed with the specific and more potent P-gp inhibitor GF120918 (4microM). Analytical quantification was achieved using high performance liquid chromatography. At a pH gradient, DEM and DOR were subject to a significant active efflux transport (Papp(B-A) > 2-3x Papp(A-B); p<0.01). However, neither the influx nor the efflux was affected by P-gp inhibitors. At physiological pH, we observed no more efflux of the drugs and no influence of the inhibitors. In conclusion, dextromethorphan and dextrorphan are not P-gp substrates. However, pH-mediated efflux mechanisms seem to be involved in limiting DEM gastrointestinal absorption. The preferential anti-NMDA central effect of DEM appears to be P-gp independent.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18288956     DOI: 10.2174/138920008783571765

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  3 in total

1.  Infant Dextromethorphan and Dextrorphan Exposure via Breast Milk From Mothers Who Are CYP2D6 Extensive Metabolizers.

Authors:  Sara Shum; Aprajita Yadav; Emily Fay; Sue Moreni; Jennie Mao; Lindsay Czuba; Celine Wang; Nina Isoherranen; Mary F Hebert
Journal:  J Clin Pharmacol       Date:  2022-01-08       Impact factor: 2.860

2.  Uptake/efflux transport of tramadol enantiomers and O-desmethyl-tramadol: focus on P-glycoprotein.

Authors:  Mouna Kanaan; Youssef Daali; Pierre Dayer; Jules Desmeules
Journal:  Basic Clin Pharmacol Toxicol       Date:  2009-05-26       Impact factor: 4.080

3.  A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women.

Authors:  Alice Ban Ke; Srikanth C Nallani; Ping Zhao; Amin Rostami-Hodjegan; Nina Isoherranen; Jashvant D Unadkat
Journal:  Drug Metab Dispos       Date:  2013-01-25       Impact factor: 3.922

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.